Defibrillation energy requirements with single endocardial (Endotak) lead

• Published in: Pacing and clinical electrophysiology Vol. 16; no. 3 Pt 2; p. 540
• Main Authors: Winter, J, Vester, E G, Kuhls, S, Kantartzis, M, Perings, C, Pauschinger, M, Strauer, B E, Bircks, W
• Format: Journal Article
• Language: English
• Published: United States 01.03.1993
• Subjects: Cardiac Pacing, Artificial - methods; Defibrillators, Implantable; Electrocardiography; Electrodes, Implanted; Equipment Design; Female; Follow-Up Studies; Humans; Intraoperative Care; Male; Middle Aged; Surface Properties; Tachycardia, Ventricular - therapy; Ventricular Fibrillation - therapy
• ISSN: 0147-8389
• DOI: 10.1111/j.1540-8159.1993.tb01622.x

The need for thoracotomy in usually high risk patients has limited the use of the implantable cardioverter defibrillator. Initial clinical results with endocardial and subcutaneous patch electrodes (SQPs) are encouraging. Using a single endocardial lead in the absence of a SQP for chronic implantation of the cardioverter defibrillator, the goal of the study was to obtain defibrillation thresholds (DFTs) of 15 Joules (J) or less and to investigate changes in DFT over time. We tested 19 consecutive patients (15 men, 4 women) age 62 +/- 8.5 years with malignant ventricular arrhythmias (14 VT/5 VF). The underlying heart disease was coronary artery disease in 15 patients, dilative cardiomyopathy in two patients, and primary electrical disease in two patients. Four patients had undergone previous cardiac surgery. Left ventricular ejection fraction ranged between 14% and 66% (39% +/- 12.6%). Pacing thresholds (0.54 +/- 0.17 V at 0.5 msec), R wave amplitude for pacemaker sensing (14.2 +/- 7.0 mV), slew rate (2.12 +/- 1.4 V/sec), and resistance (500.3 +/- 73.9 W) were sufficient in all patients. Eighteen patients met our endocardial implant criteria with a DFT < or = 15 J (10.05 +/- 4.03 J) using monophasic (14 patients) or biphasic (four patients) pulse wave forms. In the one remaining patient, with a DFT of 20 J, we implanted a SQP but there was no reduction of the DFT. All patients tested showed successful defibrillation prior to discharge. During follow-up of 88 patient-months (1-9 months), 114 spontaneous VT/VF episodes occurred in five patients and were all successfully terminated. Eleven patients with a minimum follow-up of 2 months were reassessed.